ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS)

ClinicalTrials.gov ID: NCT01786603

Public ClinicalTrials.gov record NCT01786603. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 10, 2026, 12:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 2 Study of Rasagiline for Treatment of Amyotrophic Lateral Sclerosis

Study identification

NCT ID
NCT01786603
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Richard Barohn, MD
Other
Enrollment
80 participants

Conditions and interventions

Interventions

  • Placebo Drug
  • Rasagiline Drug

Drug

Eligibility (public fields only)

Age range
21 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 20, 2013
Primary completion
Jul 26, 2016
Completion
Jul 26, 2016
Last update posted
Jan 26, 2020

2013 – 2016

United States locations

U.S. sites
10
U.S. states
9
U.S. cities
10
Facility City State ZIP Site status
Phoenix Neurological Associates Phoenix Arizona 85018
University of California - Irvine Irvine California 92868
California Pacific Medical Center San Francisco California 94115
University of Kansas Medical Center Kansas City Kansas 66160
St. Louis University St Louis Missouri 63104
University of Nebraska Omaha Nebraska 68198
Columbia University New York New York 10032
Oregon Health and Science University Portland Oregon 97239
University of Pennsylvania Philadelphia Pennsylvania 19107
UT Southwestern Medical Center Dallas Texas 75390

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01786603, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 26, 2020 · Synced May 10, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01786603 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →